Replies to post #25872 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC Another reason why we believe GCDX is a smoke screen..Who would buy a test when the state of Arizona, according to GCDX list of states excludes ARIZONA on that list..That state should be on the list...We checked on the four states William is going to start his advertising and marketing campaign..If you check those states, GCDX did not list itself as a foreign corporation doing business in those states on a legal basis..Those states do not show GCDX registering as a foreign corporation in those states.. btw..When Radient re[instates its coporation, it can change its name back to AMDL or ADI.. Since radient Pharm name can be used by anyone according to "lol" posts, it is obvious that ADI or AMDL or ProvistaDX will be used and not Radient Pharma...imo Wolf Pack

[guardiangel]

DC We will post what the skeptic stated about ADI being a wholly subsidiary of Radient..As you will see, the agreement was June 6m 2013, showing ADI as a Wholly owned subsidiary then 5 days later,ADI became a division..As you and we know..Radient can change a Wholly owned subsidiary to division at a"whim"..Proof shows that we are a Division from the 8-K..

http://www.sec.gov/Archives/edgar/data/838879/000121390013003193/f8k061113a1ex10i_radient.htm

This License Agreement (the “Agreement”), which shall be effective as of June 6th , 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

The 8=K was dated June 18, 2013...

Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements

We filed a Current Report on Form 8-K on June 11, 2013 to disclose our entry into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property.